financetom
Business
financetom
/
Business
/
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Jan 7, 2025 12:13 PM

Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. ( AVR ) with a Positive rating and a forecast of $22.

The analyst notes that Anteris Technologies’ DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028

Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems from Medtronic plc ( MDT ). and Abbott Laboratories ( ABT ) .

The analyst points out that DurAVR, positioned as an emerging next-gen TAVR player, is on track to capture 4%-5% of the U.S. TAVR market by 2030.

Despite strong data from MDT in 2024, clinicians still favor balloon-expandable (BEV) TAVR systems, of which DurAVR is set to be the second.

Also Read: Meta Drops Fact-Checking For Community Notes: Zuckerberg Sees ‘Opportunity To Restore Free Expression’

The analyst estimates that in the U.S., around 130,000 isolated aortic valve replacement (AVR) procedures are performed annually, out of about 550,000 patients with symptomatic severe aortic stenosis (ssAS). Additionally, 175,000 new ssAS patients are diagnosed each year, while 100,000 patients die annually due to lack of treatment.

Although TAVR market growth has slowed, the analyst sees the market as underpenetrated and views it as a promising target for the next-gen DurAVR platform.

In addition to its BEV delivery system, DurAVR offers superior hemodynamics and laminar blood flow, combining the best features of leading TAVR platforms for more favorable hemodynamics and a low-profile valve height.

Early clinical evidence suggests that DurAVR could outperform other leading TAVR platforms in areas such as hemodynamics, outcomes in valve-in-valve (VIV) procedures and potentially in long-term durability, thanks to the company’s proprietary ADAPT tissue technology, Miksic writes.

For FY25, the analyst estimates the company to report a loss of $(1.30) per share.

Price Action: AVR shares are trading higher by 2.67% to $5.760 at last check Tuesday.

Read now:

AMD Unveils ‘Next Generation' AI Processors, Gaming Gear Ahead Of CES 2025

Anteris logo courtesy of company

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Xencor Shares Fall After Early Commentary on Kidney Cancer Drug Trial Abstract
Xencor Shares Fall After Early Commentary on Kidney Cancer Drug Trial Abstract
Oct 14, 2025
02:12 PM EDT, 10/14/2025 (MT Newswires) -- Xencor ( XNCR ) shares fell nearly 7% in recent Tuesday trading after the company said it became aware that an investment bank had circulated its own takeaways from an abstract accepted for presentation at an upcoming scientific conference, even though the abstract has not yet been made public. The company said the...
Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance
Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance
Oct 14, 2025
Telix Pharmaceuticals ( TLX ) updated on Tuesday its commercial and operational performance for the third quarter of fiscal 2025. Telix reported third-quarter revenue of $206 million, up 53% year over year and 1% sequentially. PSMA imaging revenue increased 17% to $155 million, and RLS third-party revenue reached $47 million. • TLX is among today’s top performers. See what is...
--Emera Boosts Quarterly Dividend to CA$0.7325 per Share; Payable On and After Nov. 14 to Holders of Record as of Oct. 31
--Emera Boosts Quarterly Dividend to CA$0.7325 per Share; Payable On and After Nov. 14 to Holders of Record as of Oct. 31
Oct 14, 2025
02:14 PM EDT, 10/14/2025 (MT Newswires) -- Price: 48.59, Change: -0.32, Percent Change: -0.65 ...
The Arena Group Acquires Digital Assets of Lindy's Sports
The Arena Group Acquires Digital Assets of Lindy's Sports
Oct 14, 2025
02:11 PM EDT, 10/14/2025 (MT Newswires) -- The Arena Group Holdings ( AREN ) said Tuesday it has acquired the digital assets of Lindy's Sports to expand its Sports & Leisure vertical as part of its growth strategy. The company also said it plans to relaunch the site by the end of this month. Financial details were not disclosed. Price:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved